Benzinga··Vandana SinghTempus Expands Merck Partnership as AI Precision Medicine Gains Momentum
Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.
MRKTEMpersonalized medicineoncology